Guangyang Yin
Jiajing Hong
Guohui Shan
Cuizhu Xu
Bailin Li
Dongyu Yang- 1Department of Chinese Medicine, Changchun Fukang Hospital, Changchun, China
- 2College of Acupuncture and Massage, Changchun University of Chinese Medicine, Changchun, China
- 3Department of Endocrinology, The Third Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China
- 4Medical Record Center, The Third Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China
- 5Medical Quality Monitoring Center, The Third Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China
- 6Center of Traditional Chinese Medicine, The Third Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China
The increasing global prevalence of diabetes mellitus and its complications continues to encourage exploration of novel molecular mechanisms for their prevention and treatment. N6-methyladenosine (m6A) is a methylation modification that occurs at the N6 position of adenosine in most RNAs and represents the most prevalent internal modification of eukaryotic messenger RNA. This dynamic and reversible modification is involved in regulating nearly all aspects of RNA metabolism and therefore plays important roles in various diseases, including diabetes mellitus and its complications. The present review summarizes recent advances in understanding the functions of m6A modification, its regulators, and potential downstream targets in diabetes mellitus and diabetic complications. Notably, different—and sometimes opposite—expression patterns and regulatory roles of m6A regulators have been reported within the same disease or among diabetes-related disorders. The heterogeneity of patient tissues, cell lines, and experimental models used across studies highlights the need for further comprehensive evaluation of the roles of m6A modification in diabetes mellitus and its complications. This review provides a valuable reference for tracking recent research progress in the field of m6A modification in diabetes mellitus.
Introduction
Diabetes mellitus (DM) is an endocrine disorder characterized by abnormally high blood glucose levels, and it is estimated to affect 693 million adults by 2045 (1). Diabetes can be diagnosed based on plasma glucose criteria, including a fasting plasma glucose (FPG) level of at least 126 mg/dL, a 2-h plasma glucose (2-h PG) level of at least 200 mg/dL during an oral glucose tolerance test, or a glycated hemoglobin A1C level of at least 6.5% (2). Diabetes can be classified into the following main categories: type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), specific types of diabetes due to other causes, and gestational diabetes mellitus (GDM) (3). Diabetic complications mainly include macrovascular complications (e.g., cardiovascular disease) and microvascular complications (e.g., diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy, etc.) (1, 4). Most patients with DM develop at least one complication; moreover, cardiovascular complications are the leading cause of morbidity and mortality among patients with DM (5).
Epigenetic mechanisms regulate gene activity and organismal development, and the epigenome plays a critical role in the development of DM and certain diabetic complications, including chromatin remodeling, DNA modifications, histone alterations, non-coding RNAs, and RNA modifications (6, 7). N(6)-methyladenosine (m6A) is the most prevalent, abundant, and conserved internal co-transcriptional modification in eukaryotic RNAs (8), which participates in nearly all aspects of RNA metabolism, including splicing, transcription, transport, stability, translation, and degradation (9, 10). Studies in recent years have shown that m6A RNA modification plays important roles in various physiological and pathological conditions (11), including DM and its complications (12–14). Although several reviews have summarized the role of m6A modification in diabetes, some focused only on T2DM (15, 16). In addition, other reviews were published earlier (17, 18), and did not incorporate the most recent studies on m6A modification in diabetes and diabetes-related complications.
To comprehensively track m6A modification and emerging research trends in the diabetes field, this review summarizes recently published studies that focus on the associations between m6A RNA modification and DM or diabetes-related complications. More importantly, we present and discuss the diverse roles of m6A modification and its regulators across multiple diabetes-related diseases (Figure 1).
Figure 1. The expression and roles of some main m6A regulators (writers, erasers, and readers) in diabetes mellitus and diabetes-related complications, including diabetic retinopathy, diabetic cataract, type 2 diabetes, gestational diabetes, type 1 diabetes, diabetic nephropathy, and diabetic cardiomyopathy. The red arrow represents the up-regulation of specific m6A regulators, and the green arrow represents down-regulation. The co-occurrence of red and green arrows indicates potentially different roles of m6A regulators in one of the above diseases.
m6A modification and its regulators
The effects of m6A modification on mRNA are mediated by a group of m6A writer complex components, erasers, and readers, which catalyze, remove, and recognize m6A modifications on RNA, thereby functioning in normal physiological processes and pathological conditions, respectively (19, 20). The m6A writers constitute a multicomponent methyltransferase complex, mainly including METTL3, METTL14, WTAP, KIAA1429, RBM15, and ZC3H13. Demethylases, also termed erasers, consist of FTO and ALKBH5. Reader proteins recognize m6A-modified RNA and bind to it and include nuclear m6A readers (YTHDC1, HNRNPA2B1, and HNRNPC) and cytoplasmic m6A readers (YTHDFs, IGF2BPs, and YTHDC2) (20, 21).
The role of m6A modification and its regulators in diabetes and diabetes complications
Type 1 diabetes mellitus
Type 1 diabetes mellitus (T1DM) is one of the main forms of DM and is an autoimmune disease characterized by insulin deficiency due to pancreatic β-cell loss, leading to hyperglycemia (22). The m6A regulators YTHDC1 and HNRNPA2B1 were significantly up-regulated in peripheral blood mononuclear cells (PBMCs) of patients with T1DM compared with healthy individuals; however, METTL3 and IGF2BP2 were down-regulated in T1DM (23). The methylation levels of differentially methylated transcripts were significantly associated with their expression levels (23). Interestingly, a recent study validated that METTL3 levels increased drastically in β-cells at T1DM onset but rapidly declined with disease progression. More importantly, METTL3 regulated several key innate immune mediators at the β-cell level during the onset of T1DM in humans (12). These two studies indicate that METTL3 expression in T1DM may eventually decrease but may experience a transient increase during the early stages of the disease, potentially due to cellular stress. Furthermore, differences in sample sources may account for the varying expression levels of METTL3 observed in T1DM. Another study revealed that three tag single-nucleotide polymorphisms (SNPs) located in introns of PRRC2A and YTHDC2 were associated with T1DM risk in a Chinese cohort of 1005 patients with T1DM and 1257 controls using a genome-wide association study (GWAS) microarray (24). The variant rs2260051 of PRRC2A was correlated with increased PRRC2A mRNA expression in PBMCs from patients with T1DM (24). These genomic and transcriptomic studies suggest that m6A modification and its regulators may play important roles in the pathogenesis of T1DM and could serve as potential targets for T1DM diagnosis or treatment.
Researchers constructed a T1DM mouse model using streptozotocin intraperitoneal injection, which exhibited marked cognitive dysfunction. Streptozotocin induction significantly up-regulated the protein expression of YTHDC2 and ALKBH5, while down-regulating YTHDF1, YTHDF3, and WTAP (25). Furthermore, overexpression of YTHDF1 in the hippocampus significantly improved streptozotocin-induced diabetic cognitive dysfunction (25). Based on m6A-related studies using various sample types from both humans and mice, it can be inferred that overall m6A modification levels may be decreased in T1DM (Figure 1).
Type 2 diabetes mellitus
Type 2 diabetes mellitus (T2DM) is the most common form of diabetes, accounting for approximately 90% of patients with DM (5). T2DM is an increasingly prevalent multifactorial disease with both genetic and environmental risk factors, ultimately resulting in impaired glucose homeostasis (26). Shen et al. reported that global m6A levels were significantly lower in peripheral blood samples from patients with T2DM and diabetic rats compared with controls (Table 1). Notably, increased FTO expression may be responsible for the reduction in m6A levels in T2DM (27). Consistently, Yang et al. found decreased m6A content in blood samples from patients with T2DM, while mRNA expression levels of FTO, METTL3, METTL14, and WTAP were increased. FTO mRNA levels were positively correlated with fasting glucose levels (28). Coincidentally, Zhang et al. revealed that the m6A demethylase FTO was elevated in insulin-treated vascular smooth muscle cells (VSMCs) and in T2DM mice with intimal injury. Mechanistically, FTO knockdown increased SM22α expression, and the m6A reader IGF2BP2 enhanced SM22α mRNA stability (29). Ning et al. demonstrated that FTO expression was significantly up-regulated in trophoblasts from placentas of women with T2DM and that FTO-mediated m6A modification of SIK1 modulated placental cytotrophoblast syncytialization (30). Another study found that NR3C1 enhancement up-regulated FTO protein levels in β-cells and that the specific FTO inhibitor Dac51 effectively rescued NR3C1-induced β-cell failure, hyperglycemia, and glucose intolerance in diabetes models (31). However, another study reported opposing results regarding m6A and FTO levels in the blood of patients with T2DM. Although m6A modification levels were lower in obese and T2DM patients than in healthy controls, the demethylases FTO and ALKBH5 also showed reduced expression in the blood of both obese and T2DM patients (32). These findings suggest that decreased m6A methylation levels are consistently observed across different cohorts and sample types in T2DM, whereas the regulatory roles of FTO may be complex due to sample or cellular heterogeneity. Notably, recent research has shown that FTO preferentially produces a hemiaminal product and may function as a hydroxylase rather than a demethylase, unlike ALKBH5 (33). Therefore, further studies are required to clarify the demethylase-dependent and -independent roles of FTO in T2DM.
Table 1. The role of m6A modification and regulators in type 2 diabetes mellitus.
Methyltransferases METTL3 and METTL14 have also been widely investigated in T2DM. m6A sequencing of human T2DM islets revealed that several hypomethylated transcripts were associated with cell-cycle progression, insulin secretion, and the insulin/IGF1–AKT–PDX1 signaling pathway. Impairment of insulin/IGF1–AKT–PDX1 signaling is a recognized mechanism in T2DM, in which PDX1 regulates β-cell identity and insulin secretion (34, 35). Importantly, β-cell-specific Mettl14 knockout mice displayed reduced m6A levels and recapitulated the islet phenotype observed in human T2DM, including early diabetes onset and increased mortality (13). This study highlighted a more prominent role for METTL14 in modulating the insulin/IGF1–AKT–PDX1 axis compared with METTL3 in T2DM islets. Reduced Mettl3/Mettl14 expression was also observed in β-cells from diabetic db/db mice and patients with T2DM. Furthermore, mice with Mettl3/Mettl14 deletion in Ngn3+ endocrine progenitors developed hyperglycemia and hypoinsulinemia within 2 weeks after birth (36). This study validated the roles of Mettl3/14 in neonatal β-cell development and functional maturation.
In contrast, another study reported that m6A levels and METTL3 expression were increased in liver tissues from patients with T2DM and mice fed a high-fat diet (HFD) for 16 weeks. Moreover, hepatocyte-specific Mettl3 knockout in HFD-fed mice improved insulin sensitivity and reduced fatty acid synthesis (37). Luo et al. demonstrated that semaglutide alleviated β-cell dysfunction through METTL14 signaling in T2DM mice (38). Tao et al. showed that METTL3-mediated m6A modification of EGR1 mRNA promoted T2DM-associated vasculopathy (39). These studies suggested tissue-specific expression patterns and context-dependent functions of METTL3 and METTL14 in T2DM.
Several studies have reported the role of the methyltransferase WTAP in T2DM. WTAP was identified as being down-regulated in islet β-cells in T2DM, and islet β-cell–specific deletion of Wtap induced β-cell failure and diabetes. Moreover, Wtap-βKO mice exhibited severe hyperglycemia, which could be partially reversed by islet β-cell–specific overexpression of Mettl3 (40). The expression of NT5DC3 in blood samples could effectively distinguish patients with T2DM or T2DM-induced colon cancer from healthy volunteers, and its level was shown to be regulated by WTAP via m6A modification (41).
Other studies of T2DM focused on m6A readers. Deletion of IGF2BP2 in pancreatic β-cells led to reduced compensatory β-cell proliferation and impaired β-cell function, and IGF2BP2 directly bound to PDX1 mRNA and stimulated its translation in an m6A-dependent manner (42). Another study reported that IGF2BP2 and IGF2BP3 were up-regulated in islet samples from patients with T2DM, and a U-shaped association was observed between serum IGF2BP3 levels and the odds of T2DM in a Chinese adult population (43). YTHDC1 was found to be down-regulated in islet β-cells in T2DM, and β-cell–specific deletion of Ythdc1 resulted in β-cell failure and diabetes (44). Similarly, both m6A and YTHDC1 levels were reduced in patients with T2DM, and deletion of Ythdc1 in βKO mice caused glucose intolerance and diabetes due to decreased insulin secretion (45).
Public datasets have also been used to analyze the expression of m6A methylation regulators and their roles in gene regulation in T2DM (46, 47). The up-regulated expression of the m6A reader HNRNPC was shown to promote vascular endothelial dysfunction in T2DM by activating the PSEN1-mediated Notch pathway (46). In addition, co-expression gene analysis of m6A regulators identified several genes and pathways that have been reported to be strongly associated with T2DM (47).
Diabetic retinopathy
Diabetic retinopathy (DR) is a common and specific microvascular complication of diabetes, and remains the leading cause of preventable blindness in working-aged people (48). METTL3 is widely studied m6A methyltransferase in DR (Table 2). In retinal pigment epithelium (RPE) cells, METTL3 expression was inhibited by high-glucose (HG) treatment in an in vitro model of DR, and up-regulation of METTL3 alleviated the cytotoxic effects of HG on RPE cells. Mechanistically, METTL3 rescued cell viability in HG-treated RPE cells by targeting the miR-25-3p/PTEN/Akt signaling pathway (49). Interestingly, the PTEN/Akt signaling has been widely reported as a downstream target of miRNAs or lncRNAs in the pathogenesis and improvement of DR (50–52). Similarly, METTL3 expression was significantly down-regulated in patients with DR, DR mouse models, and HG-induced human retinal microvascular endothelial cells (HRMECs). Further experiments demonstrated that METTL3 regulated endothelial–mesenchymal transition in DR via the SNHG7/KHSRP/MKL1 axis in an m6A modification (53). Notably, the lncRNA SNHG7 has also been reported to regulate endothelial–mesenchymal transition in DR through alternative mechanisms, including miRNA-mediated pathways (54).
Table 2. The role of m6A modification and regulators in diabetic retinopathy.
Blood–retinal barrier (BRB) breakdown contributes to multiple ocular diseases, including DR. One study found that endothelial CYP2J2 overexpression maintained BRB integrity and protected against retinal ganglion cell loss. CYP2J2 up-regulated METTL3 expression and promoted ANXA1 translation via m6A modification in endothelial cells, identifying a potential pathway for alleviating BRB impairment and DR progression (55). In addition, recent studies showed that METTL3 may mitigate HG-induced ARPE-19 cell damage partly by regulating the stability of PSAT1 mRNA (56), and that the protective effect of PIEZO1 silencing was mediated by METTL3/YTHDF2-dependent m6A modification in DR (57). Public dataset analyses also revealed that Mettl3 and Wtap were significantly down-regulated in DR samples, and that Mettl3 (AUC = 0.917) and Wtap (AUC = 0.972) could serve as potential diagnostic biomarkers for DR (58). However, some studies reported contrasting findings. m6A RNA methylation levels and METTL3 expression were significantly up-regulated in pericytes and mouse retinas following diabetic stress, and pericyte-specific Mettl3 knockout inhibited diabetes-induced pericyte dysfunction and vascular complications in vivo (59). Fu et al. also reported that HG stimulation or diabetic stress increased both global m6A levels and METTL3 expression in experimental DR models (60).
The m6A reader protein YTHDF2 is the most extensively studied binding protein in DR. Circular RNA circFAT1 was significantly down-regulated in retinal proliferative fibrovascular membranes from patients with DR and in HG-induced RPE cells. circFAT1 promoted autophagy and inhibited HG-induced pyroptosis in RPE cells, potentially through regulation by the m6A reader YTHDF2 and their shared target LC3B (61). Up-regulation of KAT1 suppressed inflammation, neovascularization, and vascular leakage in retinal tissues of DR mouse models. YTHDF2 transcriptional activity was activated by KAT1 through histone acetylation of its promoter, leading to destabilization of target ITGB1 mRNA and attenuation of DR progression (62). PARP1 plays an important role in DR progression, and its inhibition prevented HG-induced inflammation, fibrosis, and angiogenesis in DR models in vivo. Moreover, YTHDF2 epigenetically suppressed m6A modification of PARP1 and regulated diabetes-induced PARP1 expression in DR (63).
A20 expression was reduced in glucose-treated retinal microglia and negatively regulated M1 polarization. The m6A demethylase ALKBH5 increased m6A modification of A20 in glucose-treated retinal microglia (64). Another demethylase, FTO, was shown to be driven by lactate-mediated histone lactylation in DR and was important for endothelial cell function by modulating CDK2 mRNA stability (65). Chen et al. demonstrated that FTO ameliorated HG-induced oxidative stress and cell apoptosis by activating the Nrf2/HO-1 signaling pathway in an m6A-dependent manner (66). These findings suggest that m6A demethylases may exert protective roles in DR.
Aberrantly up-regulated HAGLR was identified in serum samples from patients with DR and in HG-induced human RPE cells, and its knockdown attenuated HG-induced cytotoxic effects on apoptosis and pyroptosis. Furthermore, HAGLR expression was positively regulated by the m6A reader IGF2BP2 in an m6A-dependent manner (67). Zhou et al. reported that YTHDC1 overexpression impaired retinal vascular endothelial cell function by repressing CDK6 expression, suggesting a potential therapeutic target for DR (68). Chen et al. demonstrated that suppression of METTL14 improved HG-induced retinal ganglion cell damage and protected against DR by down-regulating PHLPP2 via m6A modification (69). In addition, recent research showed that urinary m6A concentration may serve as a potential diagnostic marker for DR, as measured by UPLC–MS/MS, providing a novel noninvasive diagnostic approach (70).
Collectively, these studies indicate that comprehensive evaluation of expression changes and functional roles of diverse m6A regulators across different sample types and experimental conditions is necessary in DR.
Diabetic cataract
Diabetic cataract (DC) is a major cause of vision loss in patients with diabetes and occurs earlier and progresses more rapidly than cataracts in non-diabetic patients (71). There were minority reports about m6A regulation in DC. The m6A abundance was increased in anterior lens capsules from patients with DC compared with control subjects, and ferroptosis-related pathways were associated with m6A-modified mRNAs (72). In addition, m6A regulator RBM15 was verified to be up-regulated in samples from DC patients and SRA01/04 cells with HG medium treatment (72). Similarly, METTL3 expression and global m6A levels were increased in DC tissues and in HG-induced human lens epithelial cells. METTL3 knockdown promoted proliferation and suppressed HG-induced apoptosis in lens epithelial cells (73). Dong et al. reported that elevated METTL3 contributed to DC progression via m6A modification of SIRT1 mRNA, influencing cellular autophagy and senescence (74). RBM15 was also shown to promote HG-induced lens epithelial cell injury by inducing m6A modification of PRNP during DC (75). These studies indicated that m6A modification in lens epithelial cells plays important roles in DC progression.
Gestational diabetes mellitus
Gestational diabetes mellitus (GDM) traditionally refers to abnormal glucose tolerance with onset or first recognition during pregnancy (76). The mRNA level of the methyltransferase METTL14 was significantly decreased in placental samples from patients with GDM compared with controls, and methylated RNA immunoprecipitation sequencing (MeRIP-seq) data revealed that most m6A peaks were reduced in 3’-untranslated regions (UTRs) and coding sequences (CDSs) near stop codons in placental samples from patients with GDM (77). Li et al. further demonstrated that METTL14 was down-regulated in placentas from patients with GDM and that METTL14-mediated silencing of the lncRNA XIST could alleviate GDM progression through m6A modification (78). Chen et al. constructed an in vitro GDM model using high-glucose (HG)–treated HTR8/SVneo cells. Consistently, METTL14 expression was decreased in the HG-induced GDM model and was subsequently up-regulated by fentanyl treatment. In addition, silencing of METTL14 reduced both m6A and mRNA levels in trophoblast cells, thereby neutralizing the effects of fentanyl on m6A and mRNA expression (79).
Interestingly, another study found that m6A levels were increased in cord blood samples from overweight or obese patients with GDM. Lipopolysaccharide (LPS) and glucose treatment induced increased m6A modification in human villous trophoblasts, whereas hesperidin reversed m6A levels in LPS- and HG-induced villous trophoblasts (80). Fang et al. validated that the global m6A methylation level of mRNA was significantly higher in the fetal liver of a GDM mouse model, and that up-regulated methyltransferase RBM15 suppressed insulin sensitivity and increased insulin resistance through m6A-mediated epigenetic regulation (81). Zhang et al. also reported increased m6A modification levels and METTL3 expression in placental tissues from patients with GDM, and identified circular RNA hsa_circ_0072380 as a potential downstream target (82). Collectively, these findings show contradictory results regarding m6A levels in GDM-related samples, highlighting the need for comprehensive evaluation of m6A modification and its regulators across different tissues, models, and clinical contexts in GDM.
Several bioinformatic studies have suggested that m6A modification is associated with immune infiltration and lncRNA regulation in GDM (83, 84). Differentially expressed m6A-related genes were significantly associated with monocyte infiltration in GDM, and seven genes could distinguish patients with GDM from normal controls, including CD81, CFH, FABP5, GBP1, GNG11, IL1RL1, and SLAMF6 (83). Another study identified an m6A-related module consisting of LINC00667, YTHDF3, MYC, and miR-33a-5p that could classify GDM with high accuracy (84). These findings provide novel insights and potential therapeutic targets for GDM.
Diabetic nephropathy
Diabetic nephropathy (DN), one of the major microvascular complications of diabetes, is the most common cause of end-stage renal disease in developed countries (85). METTL3 and METTL14 are the most widely studied m6A regulators in DN (Table 3). METTL3 was reported to be up-regulated in podocytes from renal biopsies of patients with DN. Furthermore, METTL3 knockout significantly reduced inflammation and apoptosis in HG-stimulated podocytes and alleviated podocyte injury and albuminuria in streptozotocin-induced diabetic mice (14). Similarly, Wang et al. found that METTL3 expression and global m6A levels were significantly elevated in DN, and that METTL3 silencing alleviated DN-induced kidney injury through YTHDF2-mediated m6A modification of PINK1 (86). Liu et al. further demonstrated that METTL3 knockout enhanced the expression of circ-0000953, which alleviated podocyte injury and autophagy dysfunction in DN (87). Silencing of METTL3 inhibited proliferation, migration, and renal fibrosis in HG-induced HK-2 cells by regulating m6A modification of WISP1 (88). However, Tang et al. reported contrasting results, showing that METTL3 overexpression alleviated renal impairment and fibrosis in vitro and in vivo by promoting m6A modification of the target NDS2 (89). These findings suggest that the function of METTL3 in DN requires further comprehensive investigation.
Table 3. The role of m6A modification and regulators in diabetic nephropathy.
In addition to METTL3, METTL14 has been widely reported to be up-regulated in the kidneys of mice and patients with DN (90, 91). Podocyte-specific deletion of METTL14 improved glomerular function and alleviated podocyte injury in mice. In vitro, METTL14 knockdown in podocytes facilitated autophagy and reduced apoptosis and inflammation under adriamycin treatment (90). Li et al. reported that METTL14 was elevated in kidneys from patients with DN and in HG-induced human renal glomerular endothelial cells, and that METTL14 aggravated renal injury and inflammation in db/db mice by regulating α-klotho expression in an m6A-dependent manner (92). Zheng et al. further demonstrated that METTL14 knockdown protected against streptozotocin-induced renal lesions and renal fibrosis in DN mice by regulating the stability and expression of TUG1 through m6A modification (93).
Conversely, other studies reported that METTL14 overexpression in HG-treated HK-2 cells led to inactivation of the PI3K/Akt signaling pathway and down-regulation of HDAC5, which are closely associated with epithelial–mesenchymal transition (EMT) in renal tubular cells during DN progression (94) EMT of renal tubular epithelial cells is a key driver of renal fibrosis in DN, and the PI3K/Akt pathway is widely involved in this process (95–97).
Other methyltransferases, including METTL16 and RBM15, were also found to be up-regulated in DN models. RBM15 silencing restored cell proliferation, reduced inflammation, and inhibited pyroptosis in HG-induced HK-2 cells (98). Coincidentally, WTAP expression was elevated in patients with DN and in HG-treated HK-2 cells, and WTAP knockdown attenuated HG-induced pyroptosis and NLRP3-related pro-inflammatory cytokine production in HK-2 cells and db/db mice (99).
Recently, multiple studies have reported that elevated WTAP expression may promote the progression and related pathological functions of DN by regulating different downstream targets via m6A modification (91, 100, 101). Jin et al. reported that adipose-derived stem cell–derived exosomal miR-204 could alleviate mitochondrial dysfunction in DN by inhibiting METTL7A-mediated m6A methylation of CIDEC (102). Although these studies revealed distinct regulatory mechanisms involving m6A methyltransferases, most methyltransferases were consistently up-regulated in DN or DN-related cellular models, leading to increased m6A modification of various downstream targets.
Fat mass and obesity-associated protein (FTO) is a widely studied m6A demethylase. Sun et al. revealed that FTO expression was significantly decreased in patients with DN, and that FTO overexpression markedly alleviated renal inflammation by increasing SOCS1 protein levels via m6A modification in db/db mice (103). FTO overexpression also alleviated kidney injury and suppressed DN-induced pyroptosis by regulating m6A modification of NLRP3 (104). Another two recent studies further validated the protective roles of FTO in DN (105, 106). However, Hu et al. demonstrated that FTO-mediated m6A modification induced up-regulation of the novel lncRNA ENST00000436340, which promoted podocyte injury in DN (107). Similarly, Lang et al. reported that FTO-mediated m6A modification of SAA2 mRNA promoted podocyte injury and inflammation in DN by activating the NF-κB signaling pathway (108). Importantly, NF-κB signaling has emerged as a promising therapeutic target for mitigating DN-associated inflammation and complications (109). Collectively, these studies indicate context-dependent and target-specific roles of FTO-mediated demethylation in DN.
m6A readers have been less extensively studied as primary regulators in DN. IGF2BP2 was shown to form an RNA–protein complex with SP1 and circUBXN7, which promoted macrophage infiltration and renal fibrosis in DN (110). In contrast, IGF2BP3-stabilized CAMK1 alleviated DN by regulating mitochondrial dynamics of renal tubule (111). Interestingly, urinary m6A levels were decreased in patients with DN and could distinguish individuals with DN from those with normal glucose tolerance (112). In addition, public datasets have been used to analyze m6A-modified gene expression in DN (113, 114). Both studies reported that m6A-related mRNAs or lncRNAs were correlated with M1 macrophage infiltration in DN; however, these findings require further experimental validation.
Diabetic cardiomyopathy
Diabetic cardiomyopathy (DCM) is a primary myocardial injury induced by diabetes, which has been defined as the presence of abnormalities in myocardial structure and function that occur in the absence of well-established cardiovascular risk factors (115). A recent study validated that the global m6A level of heart samples was relatively higher in a DCM model with leptin receptor deficiency than in normal mice, and the MeRIP-seq results of DCM and normal hearts revealed that differentially m6A-modified genes were related to cardiac fibrosis, myocardial hypertrophy, and myocardial energy metabolism in DCM (116). In addition, up-regulated FTO could improve cardiac function by reducing myocardial fibrosis and myocyte hypertrophy in this DCM model (116). However, another study found that METTL14 was down-regulated in cardiomyocytes and heart tissues of a DCM rat model with high-glucose (HG) treatment, and its overexpression suppressed pyroptosis and DCM by down-regulating the lncRNA TINCR with the participation of the m6A reader protein YTHDF2 (117). Li et al. validated that recruitment of METTL14 to Casq2 mRNA could increase its stability via m6A modification, and Casq2 might act as a potential target of the lncRNA Trdn-as, which was remarkably up-regulated in the hearts of DCM mice and cardiomyocytes treated with HG (118).
Meng et al. found that ALKBH5 reduced the mRNA stability of SPOP by decreasing m6A modification, and overexpression of SPOP could improve ferroptosis and DCM-induced myocardial dysfunction (119). Similarly, ALKBH5 was found to reduce m6A methylation levels of Kat2a mRNA, and its inhibition could effectively ameliorate HG-induced cardiomyocyte injury by suppressing ferroptosis (120). The down-regulated m6A level of cardiac tissue was further validated in HG-induced DCM mice, and ALKBH5 was up-regulated in cardiomyocytes of DCM mice and post-transcriptionally activated FOXO3 via m6A demethylation (121). It seemed that the levels of both m6A-related regulators and m6A were opposite in different DCM models; therefore, the regulatory role of m6A in diabetic cardiomyopathy needs to be comprehensively investigated.
Conclusion
Globally, the number of people with DM has quadrupled in the past three decades, and DM is the ninth major cause of death worldwide (5). However, the detailed mechanisms underlying the pathogenesis and progression of DM and its complications remain unclear. m6A RNA methylation provides new insights into the molecular mechanisms of DM and may help identify novel targets for the treatment of DM and DM-related diseases.
In this review, we summarized the different roles of m6A modification and its regulators in DM and its complications. These studies demonstrated the broad involvement of m6A modification in diabetic diseases. Moreover, m6A modification and most regulators showed similar expression signatures (up-regulation or down-regulation) or roles in specific diseases across different studies. However, some studies revealed that the same regulator might have different, or even opposite, roles within the same disease, indicating significant heterogeneity among samples, cell lines, and animal models. This suggests that systematic investigation under specific conditions using larger sample sizes, more cell types, and more sophisticated animal models is required. In addition, future studies should analyze the tissue-specific expression of m6A regulators in diabetic diseases, the RNA diversity of m6A modification, and the cell-type specificity of m6A methylation and its regulators at the single-cell level in specific tissues.
Author contributions
GY: Writing – original draft. JH: Writing – original draft. GS: Writing – review & editing. CX: Writing – review & editing. BL: Writing – review & editing. DY: Writing – review & editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This study was supported by grants from the Natural Science Foundation of Jilin Province (YDZJ2023ZYTS169).
Conflict of interest
The authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
m6A, N(6)-methyladenosine; DM, diabetes mellitus; FPG, fasting plasma glucose; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; GDM, gestational diabetes mellitus; PBMCs, peripheral blood mononuclear cells; GWAS, genome-wide association study; VSMCs, vascular smooth muscle cells; HFD, high-fat diet; DR, diabetic retinopathy; RPE, retinal pigment epithelium; HG, high-glucose; HRMECs, human retinal microvascular endothelial cells; BRB, blood–retinal barrier; DC, diabetic cataract; MeRIP-seq, methylated RNA immunoprecipitation sequencing; UTRs, untranslated regions; CDSs, coding sequences; LPS, lipopolysaccharide; DN, diabetic nephropathy; EMT, epithelial–mesenchymal transition; DCM, diabetic cardiomyopathy.
References
1. Cole JB and Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol. (2020) 16:377–90. doi: 10.1038/s41581-020-0278-5
2. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 2 Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabetes Care. (2023) 46:S19–40. doi: 10.2337/dc23-S002
3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. (2014) 37 Suppl 1:S81–90. doi: 10.2337/dc14-S081
4. Harding JL, Pavkov ME, Magliano DJ, Shaw JE, and Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. (2019) 62:3–16. doi: 10.1007/s00125-018-4711-2
5. Zheng Y, Ley SH, and Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. (2018) 14:88–98. doi: 10.1038/nrendo.2017.151
6. Ling C and Ronn T. Epigenetics in human obesity and type 2 diabetes. Cell Metab. (2019) 29:1028–44. doi: 10.1016/j.cmet.2019.03.009
7. Kowluru RA and Mohammad G. Epigenetic modifications in diabetes. Metabol: Clin Exp. (2022) 126:154920. doi: 10.1016/j.metabol.2021.154920
8. Jiang X, Liu B, Nie Z, Duan L, Xiong Q, Jin Z, et al. The role of m6A modification in the biological functions and diseases. Signal transduct target Ther. (2021) 6:74. doi: 10.1038/s41392-020-00450-x
9. Zhuang H, Yu B, Tao D, Xu X, Xu Y, Wang J, et al. The role of m6A methylation in therapy resistance in cancer. Mol Cancer. (2023) 22:91. doi: 10.1186/s12943-023-01782-2
10. Liu Y, Yang D, Liu T, Chen J, Yu J, and Yi P. N6-methyladenosine-mediated gene regulation and therapeutic implications. Trends Mol Med. (2023) 29:454–67. doi: 10.1016/j.molmed.2023.03.005
11. An Y and Duan H. The role of m6A RNA methylation in cancer metabolism. Mol Cancer. (2022) 21:14. doi: 10.1186/s12943-022-01500-4
12. De Jesus DF, Zhang Z, Brown NK, Li X, Xiao L, Hu J, et al. Redox regulation of m(6)A methyltransferase METTL3 in beta-cells controls the innate immune response in type 1 diabetes. Nat Cell Biol. (2024) 26:421–37. doi: 10.1038/s41556-024-01368-0
13. De Jesus DF, Zhang Z, Kahraman S, Brown NK, Chen M, Hu J, et al. m(6)A mRNA Methylation Regulates Human beta-Cell Biology in Physiological States and in Type 2 Diabetes. Nat Metab. (2019) 1:765–74. doi: 10.1038/s42255-019-0089-9
14. Jiang L, Liu X, Hu X, Gao L, Zeng H, Wang X, et al. METTL3-mediated m(6)A modification of TIMP2 mRNA promotes podocyte injury in diabetic nephropathy. Mol Ther. (2022) 30:1721–40. doi: 10.1016/j.ymthe.2022.01.002
15. Li YL, Zhang Y, Chen N, and Yan YX. The role of m(6)A modification in type 2 diabetes: A systematic review and integrative analysis. Gene. (2024) 898:148130. doi: 10.1016/j.gene.2024.148130
16. Zhang H, Gu Y, Gang Q, Huang J, Xiao Q, and Ha X. N6-methyladenosine RNA modification: an emerging molecule in type 2 diabetes metabolism. Front Endocrinol (Lausanne). (2023) 14:1166756. doi: 10.3389/fendo.2023.1166756
17. Geng X, Li Z, and Yang Y. Emerging role of epitranscriptomics in diabetes mellitus and its complications. Front Endocrinol (Lausanne). (2022) 13:907060. doi: 10.3389/fendo.2022.907060
18. Benak D, Benakova S, Plecita-Hlavata L, and Hlavackova M. The role of m(6)A and m(6)Am RNA modifications in the pathogenesis of diabetes mellitus. Front Endocrinol (Lausanne). (2023) 14:1223583. doi: 10.3389/fendo.2023.1223583
19. Zaccara S, Ries RJ, and Jaffrey SR. Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. (2019) 20:608–24. doi: 10.1038/s41580-019-0168-5
20. Yang Y, Hsu PJ, Chen YS, and Yang YG. Dynamic transcriptomic m(6)A decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res. (2018) 28:616–24. doi: 10.1038/s41422-018-0040-8
21. He L, Li H, Wu A, Peng Y, Shu G, and Yin G. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. (2019) 18:176. doi: 10.1186/s12943-019-1109-9
22. Katsarou A, Gudbjornsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, et al. Type 1 diabetes mellitus. Nat Rev Dis Primers. (2017) 3:17016. doi: 10.1038/nrdp.2017.16
23. Wang Y, Xu L, Luo S, Sun X, Li J, Pang H, et al. The m6A methylation profiles of immune cells in type 1 diabetes mellitus. Front Immunol. (2022) 13:1030728. doi: 10.3389/fimmu.2022.1030728
24. Chen Y, Shen M, Ji C, Huang Y, Shi Y, Ji L, et al. Genome-wide identification of N6-methyladenosine associated SNPs as potential functional variants for type 1 diabetes. Front Endocrinol. (2022) 13:913345. doi: 10.3389/fendo.2022.913345
25. Li M, Zhong X, Zhao Z, Zeng Z, Yuan Q, Xiao X, et al. The expression of m6A enzymes in the hippocampus of diabetic cognitive impairment mice and the possible improvement of YTHDF1. Brain Res. (2022) 1777:147766. doi: 10.1016/j.brainres.2021.147766
26. Krentz NAJ and Gloyn AL. Insights into pancreatic islet cell dysfunction from type 2 diabetes mellitus genetics. Nat Rev Endocrinol. (2020) 16:202–12. doi: 10.1038/s41574-020-0325-0
27. Shen F, Huang W, Huang JT, Xiong J, Yang Y, Wu K, et al. Decreased N(6)-methyladenosine in peripheral blood RNA from diabetic patients is associated with FTO expression rather than ALKBH5. J Clin Endocrinol Metab. (2015) 100:E148–154. doi: 10.1210/jc.2014-1893
28. Yang Y, Shen F, Huang W, Qin S, Huang JT, Sergi C, et al. Glucose is involved in the dynamic regulation of m6A in patients with type 2 diabetes. J Clin Endocrinol Metab. (2019) 104:665–73. doi: 10.1210/jc.2018-00619
29. Zhang BF, Wu ZH, Deng J, Jin HJ, Chen WB, Zhang S, et al. M(6)A methylation-mediated elevation of SM22alpha inhibits the proliferation and migration of vascular smooth muscle cells and ameliorates intimal hyperplasia in type 2 diabetes mellitus. Biol Chem. (2022) 403:317–29. doi: 10.1515/hsz-2021-0296
30. Ning J, Yan J, Wang S, Cui Z, Xue Y, Juan J, et al. Demethylase FTO-mediated m6A modification of SIK1 modulates placental cytotrophoblast syncytialization in type 2 diabetes mellitus. iScience. (2024) 27:109900. doi: 10.1016/j.isci.2024.109900
31. Wu T, Shao Y, Li X, Wu T, Yu L, Liang J, et al. NR3C1/Glucocorticoid receptor activation promotes pancreatic beta-cell autophagy overload in response to glucolipotoxicity. Autophagy. (2023) 19:2538–57. doi: 10.1080/15548627.2023.2200625
32. Onalan E, Yakar B, Onalan EE, Karakulak K, Kaymaz T, and Donder E. m(6)A RNA, FTO, ALKBH5 expression in type 2 diabetic and obesity patients. J Coll Physicians Surg–Pakistan: JCPSP. (2022) 32:1143–8. doi: 10.29271/jcpsp.2022.09.1143
33. Kaur S, Maheswaran P, Kaur S, Lai Y, Salah E, Zhang D, et al. Evidence human FTO catalyses hydroxylation of N6-methyladenosine without direct formation of a demethylated product contrasting with ALKBH5/2/3 and bacterial AlkB. Nucleic Acids Res. (2025) 53:gkaf813. doi: 10.1093/nar/gkaf813
34. Humphrey RK, Yu SM, Flores LE, and Jhala US. Glucose regulates steady-state levels of PDX1 via the reciprocal actions of GSK3 and AKT kinases. J Biol Chem. (2010) 285:3406–16. doi: 10.1074/jbc.M109.006734
35. Elghazi L and Bernal-Mizrachi E. Akt and PTEN: beta-cell mass and pancreas plasticity. Trends Endocrinol Metab. (2009) 20:243–51. doi: 10.1016/j.tem.2009.03.002
36. Wang Y, Sun J, Lin Z, Zhang W, Wang S, Wang W, et al. m(6)A mRNA Methylation Controls Functional Maturation in Neonatal Murine beta-Cells. Diabetes. (2020) 69:1708–22. doi: 10.2337/db19-0906
37. Xie W, Ma LL, Xu YQ, Wang BH, and Li SM. METTL3 inhibits hepatic insulin sensitivity via N6-methyladenosine modification of Fasn mRNA and promoting fatty acid metabolism. Biochem Biophys Res Commun. (2019) 518:120–6. doi: 10.1016/j.bbrc.2019.08.018
38. Luo Y, Li JE, Zeng H, Zhang Y, Yang S, and Liu J. Semaglutide alleviates the pancreatic beta cell function via the METTL14 signaling and modulating gut microbiota in type 2 diabetes mellitus mice. Life Sci. (2025) 361:123328. doi: 10.1016/j.lfs.2024.123328
39. Tao M, Shan L, Zhang W, Wei L, Guo M, Fang Z, et al. METTL3-mediated m6A modification of EGR1 mRNA promotes T2DM vasculopathy. Cell Signal. (2025) 127:111564. doi: 10.1016/j.cellsig.2024.111564
40. Li X, Yang Y, Li Z, Wang Y, Qiao J, and Chen Z. Deficiency of WTAP in islet beta cells results in beta cell failure and diabetes in mice. Diabetologia. (2023) 66:1084–96. doi: 10.1007/s00125-023-05900-z
41. Li H, Li C, Zhang B, and Jiang H. Lactoferrin suppresses the progression of colon cancer under hyperglycemia by targeting WTAP/m(6)A/NT5DC3/HKDC1 axis. J Trans Med. (2023) 21:156. doi: 10.1186/s12967-023-03983-1
42. Regue L, Zhao L, Ji F, Wang H, Avruch J, and Dai N. RNA m6A reader IMP2/IGF2BP2 promotes pancreatic beta-cell proliferation and insulin secretion by enhancing PDX1 expression. Mol Metab. (2021) 48:101209. doi: 10.1016/j.molmet.2021.101209
43. Wu X, Wang W, Fan S, You L, Li F, Zhang X, et al. U-shaped association between serum IGF2BP3 and T2DM: A cross-sectional study in Chinese population. J Diabetes. (2023) 15:349–61. doi: 10.1111/1753-0407.13378
44. Li X, Yang Y, and Chen Z. Downregulation of the m(6)A reader protein YTHDC1 leads to islet beta-cell failure and diabetes. Metabol: Clin Exp. (2023) 138:155339. doi: 10.1016/j.metabol.2022.155339
45. Yang K, Sun J, Zhang Z, Xiao M, Ren D, and Liu SM. Reduction of mRNA m(6)A associates with glucose metabolism via YTHDC1 in human and mice. Diabetes Res Clin Pract. (2023) 198:110607. doi: 10.1016/j.diabres.2023.110607
46. Cai Y, Chen T, Wang M, Deng L, Li C, Fu S, et al. N6-methylation of RNA-bound adenosine regulator HNRNPC promotes vascular endothelial dysfunction in type 2 diabetes mellitus by activating the PSEN1-mediated Notch pathway. Diabetes Res Clin Pract. (2023) 197:110261. doi: 10.1016/j.diabres.2023.110261
47. Chen C, Xiang Q, Liu W, Liang S, Yang M, and Tao J. Co-expression Network Revealed Roles of RNA m(6)A Methylation in Human beta-Cell of Type 2 Diabetes Mellitus. Front Cell Dev Biol. (2021) 9:651142. doi: 10.3389/fcell.2021.651142
48. Cheung N, Mitchell P, and Wong TY. Diabetic retinopathy. Lancet. (2010) 376:124–36. doi: 10.1016/S0140-6736(09)62124-3
49. Zha X, Xi X, Fan X, Ma M, Zhang Y, and Yang Y. Overexpression of METTL3 attenuates high-glucose induced RPE cell pyroptosis by regulating miR-25-3p/PTEN/Akt signaling cascade through DGCR8. Aging. (2020) 12:8137–50. doi: 10.18632/aging.103130
50. Zhang XL and Liu Z. MiR-19a inhibitor improves diabetic retinopathy in rats through PTEN/Akt/P-Akt signaling pathway. J Biol Regul Homeost Agents. (2020) 34:509–15. doi: 10.23812/20-77-A-60
51. Wang JJ, Chen ZL, Wang DD, Wu KF, Huang WB, and Zhang LQ. linc00174 deteriorates the pathogenesis of diabetic retinopathy via miR-26a-5p/PTEN/Akt signalling cascade-mediated pyroptosis. Biochem Biophys Res Commun. (2022) 630:92–100. doi: 10.1016/j.bbrc.2022.09.016
52. Zhang X, Yang Y, and Feng Z. Suppression of microRNA-495 alleviates high-glucose-induced retinal ganglion cell apoptosis by regulating Notch/PTEN/Akt signaling. BioMed Pharmacother. (2018) 106:923–9. doi: 10.1016/j.biopha.2018.07.018
53. Cao X, Song Y, Huang LL, Tian YJ, Wang XL, and Hua LY. m(6)A transferase METTL3 regulates endothelial-mesenchymal transition in diabetic retinopathy via lncRNA SNHG7/KHSRP/MKL1 axis. Genomics. (2022) 114:110498. doi: 10.1016/j.ygeno.2022.110498
54. Cao X, Xue LD, Di Y, Li T, Tian YJ, and Song Y. MSC-derived exosomal lncRNA SNHG7 suppresses endothelial-mesenchymal transition and tube formation in diabetic retinopathy via miR-34a-5p/XBP1 axis. Life Sci. (2021) 272:119232. doi: 10.1016/j.lfs.2021.119232
55. Zhao B, Huang J, Lou X, Yao K, Ye M, Mou Q, et al. Endothelial CYP2J2 overexpression restores the BRB via METTL3-mediated ANXA1 upregulation. FASEB j: Off Publ Fed Am Soc Exp Biol. (2022) 36:e22619. doi: 10.1096/fj.202201061RR
56. Du X, Wang Y, and Gao F. PSAT1 is upregulated by METTL3 to attenuate high glucose-induced retinal pigment epithelial cell apoptosis and oxidative stress. Diagn Pathol. (2024) 19:138. doi: 10.1186/s13000-024-01556-4
57. Han N, Yu N, and Yu L. The mRNA Stability of PIEZO1, Regulated by Methyltransferase-Like 3 via N(6)-Methylation of Adenosine Modification in a YT521-B Homology Domain Family 2-Dependent Manner, Facilitates the Progression of Diabetic Retinopathy. Am J Pathol. (2025) 195:265–80. doi: 10.1016/j.ajpath.2024.10.007
58. Wang X, Li X, Zong Y, Yu J, Chen Y, Zhao M, et al. Identification and validation of genes related to RNA methylation modification in diabetic retinopathy. Curr eye Res. (2023) 48:1034–49. doi: 10.1080/02713683.2023.2238144
59. Suo L, Liu C, Zhang QY, Yao MD, Ma Y, Yao J, et al. METTL3-mediated N(6)-methyladenosine modification governs pericyte dysfunction during diabetes-induced retinal vascular complication. Theranostics. (2022) 12:277–89. doi: 10.7150/thno.63441
60. Fu S, Zhou Q, Peng X, Hu Y, Xiong J, and Liu F. METTL3/YTHDC1 mediates up-regulation of lncRNA OGRU in an m6A-dependent manner involving in oxidative stress and inflammation of HG-induced Muller cells. Immunol Lett. (2025) 272:106972. doi: 10.1016/j.imlet.2025.106972
61. Huang C, Qi P, Cui H, Lu Q, and Gao X. CircFAT1 regulates retinal pigment epithelial cell pyroptosis and autophagy via mediating m6A reader protein YTHDF2 expression in diabetic retinopathy. Exp eye Res. (2022) 222:109152. doi: 10.1016/j.exer.2022.109152
62. Qi Y, Yao R, Zhang W, and Cui Q. KAT1 triggers YTHDF2-mediated ITGB1 mRNA instability to alleviate the progression of diabetic retinopathy. Pharmacol Res. (2021) 170:105713. doi: 10.1016/j.phrs.2021.105713
63. Sun J, Liu G, Chen R, Zhou J, Chen T, Cheng Y, et al. PARP1 is upregulated by hyperglycemia via N6-methyladenosine modification and promotes diabetic retinopathy. Discov Med. (2022) 34:115–29.
64. Chen T, Zhu W, Wang C, Dong X, Yu F, Su Y, et al. ALKBH5-mediated m(6)A modification of A20 regulates microglia polarization in diabetic retinopathy. Front Immunol. (2022) 13:813979. doi: 10.3389/fimmu.2022.813979
65. Chen X, Wang Y, Wang JN, Zhang YC, Zhang YR, Sun RX, et al. Lactylation-driven FTO targets CDK2 to aggravate microvascular anomalies in diabetic retinopathy. EMBO Mol Med. (2024) 16:294–318. doi: 10.1038/s44321-024-00025-1
66. Cheng Q, Zhou L, Fan X, Ma M, Zhang C, Zha X, et al. FTO-mediated Nrf2 demethylation alleviates high glucose-induced oxidative stress and apoptosis in retinal pigment epithelial cells. Mol Biol Rep. (2025) 52:289. doi: 10.1007/s11033-025-10400-x
67. Luo R, Li L, Han Q, Fu J, and Xiao F. HAGLR, stabilized by m6A modification, triggers PTEN-Akt signaling cascade-mediated RPE cell pyroptosis via sponging miR-106b-5p. J Biochem Mol Toxicol. (2024) 38:e23596. doi: 10.1002/jbt.23596
68. Zhou Q, Tian M, Cao Y, Tang M, Xiang X, Guo L, et al. YTHDC1 aggravates high glucose-induced retinal vascular endothelial cell injury via m6A modification of CDK6. Biol Direct. (2024) 19:54. doi: 10.1186/s13062-024-00498-7
69. Chen L, Wei T, Liu X, Cui L, Hu C, and Quan Y. Methyltransferase-like enzyme 14 exacerbates retinal ganglion cell damage and diabetic retinopathy through N6-methyladenosine-dependent upregulation of pleckstrin homology domain and leucine rich repeat protein phosphatase 2. Toxicol Appl Pharmacol. (2025) 498:117304. doi: 10.1016/j.taap.2025.117304
70. Yao C, Lv D, Zhou X, Fu P, Sun W, Chen J, et al. Exploring urinary modified nucleosides as biomarkers for diabetic retinopathy: Development and validation of a ultra performance liquid chromatography-tandem mass spectrometry method. J Chromatogr B Anal Technol Biomed Life Sci. (2024) 1232:123968. doi: 10.1016/j.jchromb.2023.123968
71. Xia Y. The management of cataract surgery in diabetic patients. J perioperative Pract. (2022) 32:361–7. doi: 10.1177/17504589221091063
72. Cai L, Han XY, Li D, Ma DM, Shi YM, Lu Y, et al. Analysis of N6-methyladenosine-modified mRNAs in diabetic cataract. World J Diabetes. (2023) 14:1077–90. doi: 10.4239/wjd.v14.i7.1077
73. Yang J, Liu J, Zhao S, and Tian F. N(6)-methyladenosine METTL3 modulates the proliferation and apoptosis of lens epithelial cells in diabetic cataract. Mol Ther Nucleic Acids. (2020) 20:111–6. doi: 10.1016/j.omtn.2020.02.002
74. Dong S, Zhang J, Fu Y, Tang G, Chen J, Sun D, et al. METTL3-mediated m6A modification of SIRT1 mRNA affects the progression of diabetic cataracts through cellular autophagy and senescence. J Transl Med. (2024) 22:865. doi: 10.1186/s12967-024-05691-w
75. Xie P, He J, and Ou Y. RBM15 promotes high glucose-induced lens epithelial cell injury by inducing PRNP N6-methyladenine modification during diabetic cataract. Curr Eye Res. (2024) 49:1145–53. doi: 10.1080/02713683.2024.2362855
76. Sweeting A, Wong J, Murphy HR, and Ross GP. A clinical update on gestational diabetes mellitus. Endoc Rev. (2022) 43:763–93. doi: 10.1210/endrev/bnac003
77. Wang J, Wang K, Liu W, Cai Y, and Jin H. m6A mRNA methylation regulates the development of gestational diabetes mellitus in Han Chinese women. Genomics. (2021) 113:1048–56. doi: 10.1016/j.ygeno.2021.02.016
78. Li Y, Liu Y, Yao X, Wang H, Shi Z, and He M. METTL14-mediated lncRNA XIST silencing alleviates GDM progression by facilitating trophoblast cell proliferation and migration via the miR-497-5p/FOXO1 axis. J Biochem Mol Toxicol. (2024) 38:e23621. doi: 10.1002/jbt.23621
79. Chen Y, Lv G, Du X, Yang F, and Zhao Z. Fentanyl promoted the growth of placenta trophoblast cells through regulating the METTL14 mediated CCL5 levels. Biol Pharm Bull. (2023) 46:1797–804. doi: 10.1248/bpb.b23-00531
80. Chen Q, Hu K, Shi J, Li H, and Li W. Hesperidin inhibits methylation and autophagy in LPS and high glucose-induced human villous trophoblasts. Biochem Biophys Res Commun. (2023) 671:278–85. doi: 10.1016/j.bbrc.2023.05.117
81. Fang J, Wu X, He J, Zhang H, Chen X, Novakovic B, et al. RBM15 suppresses hepatic insulin sensitivity of offspring of gestational diabetes mellitus mice via m6A-mediated regulation of CLDN4. Mol Med. (2023) 29:23. doi: 10.1186/s10020-023-00615-8
82. Zhang S, Cai S, Ye L, Shen L, Zhu C, Huang J, et al. METTL3 mediates m6A modification of hsa_circ_0072380 to regulate the progression of gestational diabetes mellitus. Gene. (2024) 931:148894. doi: 10.1016/j.gene.2024.148894
83. Du R, Li L, and Wang Y. N6-methyladenosine-related gene signature associated with monocyte infiltration is clinically significant in gestational diabetes mellitus. Front Endocrinol (Lausanne). (2022) 13:853857. doi: 10.3389/fendo.2022.853857
84. Du R, Bai Y, and Li L. Biological networks in gestational diabetes mellitus: insights into the mechanism of crosstalk between long non-coding RNA and N(6)-methyladenine modification. BMC Preg Childbirth. (2022) 22:384. doi: 10.1186/s12884-022-04716-w
85. Flyvbjerg A. The role of the complement system in diabetic nephropathy. Nat Rev Nephrol. (2017) 13:311–8. doi: 10.1038/nrneph.2017.31
86. Wang F, Bai J, Zhang X, Wang D, Xue J, Chen H, et al. METTL3/YTHDF2 m6A axis mediates the progression of diabetic nephropathy through epigenetically suppressing PINK1 and mitophagy. J Diabetes Invest. (2024) 15(3):288–99. doi: 10.1111/jdi.14113
87. Liu X, Jiang L, Zeng H, Gao L, Guo S, Chen C, et al. Circ-0000953 deficiency exacerbates podocyte injury and autophagy disorder by targeting Mir665-3p-Atg4b in diabetic nephropathy. Autophagy. (2024) 2023:1–26. doi: 10.1080/15548627.2023.2286128
88. Chen Y, Li P, Lin M, Jiang Y, Tan G, Huang L, et al. Silencing of METTL3 prevents the proliferation, migration, epithelial-mesenchymal transition, and renal fibrosis of high glucose-induced HK2 cells by mediating WISP1 in m6A-dependent manner. Aging (Albany NY). (2024) 16:1237–48. doi: 10.18632/aging.205401
89. Tang W, Zhao Y, Zhang H, Peng Y, and Rui Z. METTL3 enhances NSD2 mRNA stability to reduce renal impairment and interstitial fibrosis in mice with diabetic nephropathy. BMC Nephrol. (2022) 23:124. doi: 10.1186/s12882-022-02753-3
90. Lu Z, Liu H, Song N, Liang Y, Zhu J, Chen J, et al. METTL14 aggravates podocyte injury and glomerulopathy progression through N(6)-methyladenosine-dependent downregulating of Sirt1. Cell Death Dis. (2021) 12:881. doi: 10.1038/s41419-021-04156-y
91. Fu K, Jing C, Shi J, Mao S, Lu R, Yang M, et al. WTAP and METTL14 regulate the m6A modification of DKK3 in renal tubular epithelial cells of diabetic nephropathy. Biochem Biophys Res Commun. (2024) 738:150524. doi: 10.1016/j.bbrc.2024.150524
92. Li M, Deng L, and Xu G. METTL14 promotes glomerular endothelial cell injury and diabetic nephropathy via m6A modification of alpha-klotho. Mol Med. (2021) 27:106. doi: 10.1186/s10020-021-00365-5
93. Zheng Y, Zhang Z, Zheng D, Yi P, and Wang S. METTL14 promotes the development of diabetic kidney disease by regulating m(6)A modification of TUG1. Acta diabetol. (2023) 60:1567–80. doi: 10.1007/s00592-023-02145-5
94. Xu Z, Jia K, Wang H, Gao F, Zhao S, Li F, et al. METTL14-regulated PI3K/Akt signaling pathway via PTEN affects HDAC5-mediated epithelial-mesenchymal transition of renal tubular cells in diabetic kidney disease. Cell Death Dis. (2021) 12:32. doi: 10.1038/s41419-020-03312-0
95. Lu Q, Wang WW, Zhang MZ, Ma ZX, Qiu XR, Shen M, et al. ROS induces epithelial-mesenchymal transition via the TGF-beta1/PI3K/Akt/mTOR pathway in diabetic nephropathy. Exp Ther Med. (2019) 17:835–46. doi: 10.3892/etm.2018.7014
96. Wang H, Gao L, Zhao C, Fang F, Liu J, Wang Z, et al. The role of PI3K/Akt signaling pathway in chronic kidney disease. Int Urol Nephrol. (2024) 56:2623–33. doi: 10.1007/s11255-024-03989-8
97. Xue M, Cheng Y, Han F, Chang Y, Yang Y, Li X, et al. Triptolide attenuates renal tubular epithelial-mesenchymal transition via the miR-188-5p-mediated PI3K/AKT pathway in diabetic kidney disease. Int J Biol Sci. (2018) 14:1545–57. doi: 10.7150/ijbs.24032
98. Qin Y, Wu S, Zhang F, Zhou X, You C, and Tan F. N6-methyladenosine methylation regulator RBM15 promotes the progression of diabetic nephropathy by regulating cell proliferation, inflammation, oxidative stress, and pyroptosis through activating the AGE-RAGE pathway. Environ Toxicol. (2023) 38:2772–82. doi: 10.1002/tox.23917
99. Lan J, Xu B, Shi X, Pan Q, and Tao Q. WTAP-mediated N(6)-methyladenosine modification of NLRP3 mRNA in kidney injury of diabetic nephropathy. Cell Mol Biol Lett. (2022) 27:51. doi: 10.1186/s11658-022-00350-8
100. Bai Y, Huang L, Fan Y, and Li Y. Marrow mesenchymal stem cell mediates diabetic nephropathy progression via modulation of Smad2/3/WTAP/m6A/ENO1 axis. FASEB J. (2024) 38:e23729. doi: 10.1096/fj.202301773R
101. Zhang Z, Zhou F, Lu M, Zhang D, Zhang X, Xu S, et al. WTAP-mediated m(6)A modification of TRIM22 promotes diabetic nephropathy by inducing mitochondrial dysfunction via ubiquitination of OPA1. Redox Rep. (2024) 29:2404794. doi: 10.1080/13510002.2024.2404794
102. Jin J, Shang Y, Zheng S, Dai L, Tang J, Bian X, et al. Exosomes as nanostructures deliver miR-204 in alleviation of mitochondrial dysfunction in diabetic nephropathy through suppressing methyltransferase-like 7A-mediated CIDEC N6-methyladenosine methylation. Aging (Albany NY). (2024) 16:3302–31. doi: 10.18632/aging.205535
103. Sun Q, Geng H, Zhao M, Li Y, Chen X, Sha Q, et al. FTO-mediated m(6) A modification of SOCS1 mRNA promotes the progression of diabetic kidney disease. Clin Trans Med. (2022) 12:e942. doi: 10.1002/ctm2.942
104. Li Q and Mu S. FTO mediates the diabetic kidney disease progression through regulating the m(6)A modification of NLRP3. BMC Nephrol. (2024) 25:345. doi: 10.1186/s12882-024-03741-5
105. Zhu S, Jiang L, Liu X, Chen C, Luo X, Jiang S, et al. m6A demethylase Fto inhibited macrophage activation and glycolysis in diabetic nephropathy via m6A/Npas2/Hif-1alpha axis. FASEB J. (2025) 39:e70332. doi: 10.1096/fj.202403014R
106. Chang K, Hong F, Liu H, Fang Y, Wang H, Song N, et al. FTO aggravates podocyte injury and diabetic nephropathy progression via m6A-dependent stabilization of ACC1 mRNA and promoting fatty acid metabolism. Biochem Pharmacol. (2025) 235:116819. doi: 10.1016/j.bcp.2025.116819
107. Hu J, Wang Q, Fan X, Zhen J, Wang C, Chen H, et al. Long noncoding RNA ENST00000436340 promotes podocyte injury in diabetic kidney disease by facilitating the association of PTBP1 with RAB3B. Cell Death Dis. (2023) 14:130. doi: 10.1038/s41419-023-05658-7
108. Lang Y, Wang Q, Sheng Q, Lu S, Yang M, Kong Z, et al. FTO-mediated m6A modification of serum amyloid A2 mRNA promotes podocyte injury and inflammation by activating the NF-kappaB signaling pathway. FASEB J. (2024) 38:e23409. doi: 10.1096/fj.202301419RR
109. Abhirami BL, Krishna AA, Kumaran A, and Chiu CH. Targeting NF-kappaB in diabetic nephropathy: exploring the therapeutic potential of phytoconstituents. Arch Pharm Res. (2025) 48:577–637. doi: 10.1007/s12272-025-01555-z
110. Lin Z, Lv D, Liao X, Peng R, Liu H, Wu T, et al. CircUBXN7 promotes macrophage infiltration and renal fibrosis associated with the IGF2BP2-dependent SP1 mRNA stability in diabetic kidney disease. Front Immunol. (2023) 14:1226962. doi: 10.3389/fimmu.2023.1226962
111. Yuan D, Li H, Dai W, Zhou X, Zhou W, and He L. IGF2BP3-stabilized CAMK1 regulates the mitochondrial dynamics of renal tubule to alleviate diabetic nephropathy. Biochim Biophys Acta Mol Basis Dis. (2024) 1870:167022. doi: 10.1016/j.bbadis.2024.167022
112. Wan SJ, Hua Q, Xing YJ, Cheng Y, Zhou SM, Sun Y, et al. Decreased Urine N6-methyladenosine level is closely associated with the presence of diabetic nephropathy in type 2 diabetes mellitus. Front Endocrinol. (2022) 13:986419. doi: 10.3389/fendo.2022.986419
113. Li C, Su F, Liang Z, Zhang L, Liu F, Fan W, et al. Macrophage M1 regulatory diabetic nephropathy is mediated by m6A methylation modification of lncRNA expression. Mol Immunol. (2022) 144:16–25. doi: 10.1016/j.molimm.2022.02.008
114. Yin S, Li W, Wang J, Wu H, Hu J, and Feng Y. Screening of key genes associated with m6A methylation in diabetic nephropathy patients by CIBERSORT and weighted gene coexpression network analysis. Am J Trans Res. (2022) 14:2280–90.
115. Peterson LR and Gropler RJ. Metabolic and molecular imaging of the diabetic cardiomyopathy. Circ Res. (2020) 126:1628–45. doi: 10.1161/CIRCRESAHA.120.315899
116. Ju W, Liu K, Ouyang S, Liu Z, He F, and Wu J. Changes in N6-methyladenosine modification modulate diabetic cardiomyopathy by reducing myocardial fibrosis and myocyte hypertrophy. Front Cell Dev Biol. (2021) 9:702579. doi: 10.3389/fcell.2021.702579
117. Meng L, Lin H, Huang X, Weng J, Peng F, and Wu S. METTL14 suppresses pyroptosis and diabetic cardiomyopathy by downregulating TINCR lncRNA. Cell Death Dis. (2022) 13:38. doi: 10.1038/s41419-021-04484-z
118. Li X, Liu L, Lou H, Dong X, Hao S, Sun Z, et al. Cardiomyocyte-specific long noncoding RNA Trdn-as induces mitochondrial calcium overload by promoting the m(6)A modification of calsequestrin 2 in diabetic cardiomyopathy. Front Med. (2025) 19:329–46. doi: 10.1007/s11684-024-1102-6
119. Meng W and Li L. N6-methyladenosine modification of SPOP relieves ferroptosis and diabetic cardiomyopathy by enhancing ubiquitination of VDAC3. Free Radic Biol Med. (2025) 226:216–29. doi: 10.1016/j.freeradbiomed.2024.11.025
120. Zhen J, Sheng X, Chen T, and Yu H. Histone acetyltransferase Kat2a regulates ferroptosis via enhancing Tfrc and Hmox1 expression in diabetic cardiomyopathy. Cell Death Dis. (2024) 15:406. doi: 10.1038/s41419-024-06771-x
Keywords: diabetes complications, diabetes mellitus, m6A, m6A regulators, methyladenosine
Citation: Yin G, Hong J, Shan G, Xu C, Li B and Yang D (2026) The latest progression of N6-methyladenosine (m6A) RNA modification in diabetes mellitus and diabetic complications. Front. Endocrinol. 16:1705600. doi: 10.3389/fendo.2025.1705600
Received: 30 September 2025; Accepted: 09 December 2025; Revised: 04 December 2025;
Published: 09 January 2026.
Edited by:
Bodhini Dhanasekaran, Madras Diabetes Research Foundation, IndiaReviewed by:
Dario F. De Jesus, The University of Chicago, United StatesKonda Mani Saravanan, Bharath Institute of Higher Education and Research, India
Copyright © 2026 Yin, Hong, Shan, Xu, Li and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Dongyu Yang, MTMzMzE3Njk1OThAMTYzLmNvbQ==
†These authors have contributed equally to this work